Hypertension Registry of "Hypertension Prevention and Control Initiative in China"
Hypertension Registry of "Hypertension Prevention and Control Initiative in China"
Hypertension is the leading preventable risk factor of cardiovascular disease globally and in
 China. Unparalleled to remarkable increase of hypertension burden in China, blood
 pressure(BP) control is inadequate. A political public health project, "Hypertension
 Prevention and Control Initiative in China(Chronic Disease Demonstration District
 Construction)", was initiated in October 2019 for explore a feasible and reproducible
 archetype for hypertension management and to improve the registration, management, treatment
 and control rates of hypertension in China. The project is designed to consecutively
 implement health service strategies in 40 pilot counties covering 31 provinces and around
 200,000 hypertension patients in mainland China, via the National Medical Alliance for
 Hypertension(NMAH). The Hypertension Registry study aims to registry, follow up and observe
 the clinical features, treatment, blood pressure control and outcomes of all hypertension
 patients managed in the "Hypertension Prevention and Control Initiative in China" project.
Objective: The study aims to investigate the clinical features, treatment, blood pressure
 control and outcomes of hypertension patients managed in the "Hypertension Prevention and
 Control Initiative in China" project.

 Study Type: A national, multicenter, observational, prospective cohort study.

 Study Design: The cardinal contents of this registry study are as follows:

 Introduce the Digital Information System and train in completing case report forms.

 Collect sociodemographic information, lifestyle behaviors, self-reported personal medical
 history, BP, anthropometric measurements, medication at registration, laboratory
 investigations of hypertension patients managed in the "Hypertension Prevention and Control
 Initiative in China" project. Build a baseline database of hypertension patients.

 Gather the follow up information including general, clinical, therapeutic, prognostic data of
 all recruits at 3-month intervals over 2 years and build up the follow-up database.

 Data management, quality control and statistic analysis: Digital Information Platform for
 data capture, document and cloud computing has been built and the investigators will manage
 and analyze data in align with key indicators. The investigators have invited professional
 statistic analysts to assist analyzing data and a third party to supervise data quality.

 Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before
 patient enrollment are required.
Inclusion Criteria:

 1. Age ≥ 18 years.

 2. Residing in the local administrative area for at least 6 months.

 3. Hypertension：defined as systolic blood pressure (SBP) ≥140 mmHg and/or /diastolic
 blood pressure (DBP) ≥90 mmHg and/or use of antihypertensive medication within two
 weeks.

 4. Informed consent.

 Exclusion Criteria:

 1. patients under pregnancy or lactation.

 2. patients with severe liver or renal diseases.

 3. patients with history of malignant tumor.

 4. patients with mental illness that impair their consent.